Bioton SA operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bioton SA with three other
pharmaceutical manufacturers in Europe:
sales of 89.50 million Euro [US$101.24 million]
of which 104%
was EVT Execute),
(395.79 million Romanian Leu [US$100.63 million]
based in Latvia
(93.66 million Euro [US$105.94 million]
During the year ended December of 2014, sales at
Bioton SA were 377.30 million Polish New Zlotys (US$104.78 million).
increase of 10.9%
versus 2013, when the company's sales were 340.36 million Polish New Zlotys.
Despite this increase, sales are still
below the level achieved in 2012, when Bioton SA
reported sales of 406.30 million Polish New Zlotys.
Sales of Copernicus saw an increase
that was more than double the company's growth rate: sales were up
934.4% in 2014, from
64,000.00 Polish New Zlotys to 662,000.00 Polish New Zlotys.
Bioton SA also saw significant increases in sales in
Scigen Group (up 19.0% to 73.32 million Polish New Zlotys)
Pharmatex (up 65.2% to 43.18 million Polish New Zlotys)
Fisiopharma (up 19.4% to 22.63 million Polish New Zlotys)
Biolek (up 785.5% to 549,000.00 Polish New Zlotys)
Bioton Trade (up 550.0% to 13,000.00 Polish New Zlotys)
Not all segments of Bioton SA experienced an increase in sales in 2014:
sales of Mj Biopharm fell 7.6% to 68.00 million Polish New Zlotys.